Article
The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL.
Leukemia - 1 Sept 2009
Mian A A, Schüll M, Zhao Z, Oancea C, Hundertmark A, Beissert T, Ottmann O G, Ruthardt M
Abstract excerpt
In Philadelphia chromosome-positive (Ph+) leukemia BCR/ABL induces the leukemic phenotype. Targeted inhibition of BCR/ABL by kinase inhibitors leads to complete remission. However, patients with advanced Ph+ leukemia relapse and acquire resistance, mainly due to point mutations in BCR/ABL. The 'gatekeeper mutation' T315I is responsible for a general resistance to small molecules. It seems not only to decrease the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.